The state-run Israel Institute for Biological Research announced on Sunday that researchers will begin human testing on its coronavirus vaccine next week.
The institute said clinical tests on an initial group of 80 people would begin on November 1. The testing is to expand to a second phase of 960 people in December, with a third and final phase of 30,000 people next April or May depending on the results of the earlier phases.
I believe in the abilities of our scientists and I am confident that we can produce a safe and effective vaccine, said Dr Shmuel Shapira, director of the institute.
He said the goal is to produce 15 million doses for the benefit of the residents of the state of Israel and our close neighbours. He did not elaborate.
The institute is run by the Defence Ministry. This is a day of hope for the citizens of Israel, said Defence Minister Benny Gantz.
Over 40 coronavirus vaccine candidates are in clinical trials worldwide, according to the World Health Organisation.
Israel, a country of about 9 million people, has reported over 300,000 cases of COVID-19 and nearly 2,400 deaths.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU